AXSM — AXSOME THERAPEUTICS INC (Healthcare >> Biotechnology)
AXSM FAQ
What is AXSM's ROE?
AXSOME THERAPEUTICS INC reports a Return on Equity (ROE) of -344.96%.
What is AXSM's dividend yield?
AXSOME THERAPEUTICS INC offers a dividend yield of 0.00%.
What is AXSM's Deepscope Quality Score?
Deepscope rates AXSM's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AXSM?
Deepscope's AI Timing Score for AXSM is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AXSM belong to?
AXSOME THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 233.49
Price
11.33
(5.10%)
Day Change
|
|
|---|
AXSM, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | In "Invest - GROWTH" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 233.49 |
| PBV / Sector |
209.43 / 4.48
|
| Earning Per Share | -3.85 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
136.71 M
GREAT
|
| Average 1W Daily Value |
144.78 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:23:39 |
| Symbol | AXSM |
| Name | AXSOME THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 51.46 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11,432.30 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One World Trade Center, New York, NY, United States, 10007
Phone: 212 332 3241
Website: https://www.axsome.com
Employees: 1,220
Sector: Healthcare >> Biotechnology
Description: Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google